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The enduring suspicion that infections and immunologic response may play a role in the
etiology of childhood leukemia, particularly acute lymphoblastic leukemia (ALL), is now
supported, albeit still indirectly, by numerous epidemiological studies. The cumulative evi-
dence includes, for example, descriptive observations of a peculiar peak incidence at age
2–5 years for ALL in economically developed countries, clustering of cases in situations of
population mixing associated with unusual patterns of personal contacts, associations with
various proxy measures for immune modulatory exposures early in life, and genetic sus-
ceptibility conferred by variation in genes involved in the immune system. In this review, our
focus is the extended major histocompatibility complex (MHC), an approximately 7.6 Mb
region that is well-known for its high-density of expressed genes, extensive polymorphisms
exhibiting complex linkage disequilibrium patterns, and its disproportionately large num-
ber of immune-related genes, including human leukocyte antigen (HLA). First discovered
through the role they play in transplant rejection, the classical HLA class I (HLA-A, -B, and
-C) and class II (HLA-DR, HLA-DQ, and HLA-DP) molecules reside at the epicenter of the
immune response pathways and are now the targets of many disease susceptibility stud-
ies, including those for childhood leukemia. The genes encoding the HLA molecules are
only a minority of the over 250 expressed genes in the xMHC, and a growing number
of studies are beginning to evaluate other loci through targeted investigations or utilizing
a mapping approach with a comprehensive screen of the entire region. Here, we review
the current epidemiologic evidence available to date regarding genetic variation contained
within this highly unique region of the genome and its relationship with childhood ALL risk.
Keywords: childhood leukemia, epidemiology, genetic susceptibility, human leukocyte antigen, major
histocompatibility complex
INTRODUCTION
Leukemia, a cancer of the hematopoietic system, is the most com-
mon malignancy affecting children less than 15 years of age. Acute
lymphoblastic leukemia (ALL) comprises nearly 80% of child-
hood leukemia diagnoses in developed countries, followed by
acute myeloid leukemia (16%) and the very rare chronic sub-types
(1, 2). Pediatric patients usually exhibit characteristic chromo-
somal aberrations such as hyperdiploidy and/or translocations
[e.g., t (12;21) TEL-AML1, 11q23MLL-AF4, t (8;21) AML1-ETO,
t (15;17) PML-RARA, inv(16) CPFB-MYH11] (3), most of which
have been shown to originate prenatally due to unknown causes
(2). These prenatal chromosomal aberrations are likely initiating
genetic events, occurring during fetal hematopoiesis and operat-
ing within a minimal two-hit disease model. Current evidence
indicates that transition to overt disease will occur in only a small
proportion of children carrying this pre-leukemic clone, after a
sufficient second genetic event which likely occurs postnatally as a
consequence of a mutagenic exposure (2, 4).
One potential post-natal exposure long thought to modulate
this second “hit” is exposure to infectious agents, a premise based
on early studies demonstrating the ability of certain viruses to
cause leukemia in animals (5, 6) and observing an age distribution
that closely mimics the incidence of common childhood infectious
diseases (7). In the absence of direct evidence for the involvement
of a specific infection (8), this immunologic hypothesis describ-
ing a role of infections in childhood leukemia, particularly B-cell
precursor (BCP) ALL, has persisted as a result of accumulating
epidemiological evidence largely driven by two related infectious
hypotheses proposed in the late 1980s. Kinlen proposed the “pop-
ulation mixing” hypothesis in response to childhood leukemia
clusters occurring in Seascale and Thurso (UK), and explained
that the rise in childhood leukemia incidence may have resulted
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from children experiencing an abnormal immune response to spe-
cific infections introduced during an influx of infected persons
into an area populated with non-immune, thus susceptible indi-
viduals (9). Greaves posited his “delayed infection” hypothesis in
the context of the two-hit disease model, describing that the sec-
ond genetic hit leading to overt disease in a small fraction (∼1%)
of pre-leukemia carriers may be caused by an adverse immune
response to infections as a result of insufficient priming of the
immune system in early life (10). Abundant epidemiological data
are currently available in support of both the population mixing
(11) and delayed infection hypotheses (12). Furthermore, new evi-
dence has emerged suggesting that immune dysregulation caused
by an infectious exposure in the first months of life may lead
to an increased risk of ALL in a genetically susceptible subset of
children (2, 13).
Findings from genetic susceptibility studies targeting immune-
related genetic loci have also fueled an ongoing suspicion of a role
for immunologic response involving infections. Foremost among
the candidate loci are those residing within the major histocompat-
ibility complex (MHC), a genomic region well-known for its high-
density of genes, complex linkage disequilibrium (LD), and highly
polymorphic nature. The human MHC region spans approxi-
mately 4 Mb on the short arm of chromosome 6 (6p21.3) and
contains about 250 gene loci (Figure 1), with a disproportionately
large number encoding genes that play a role in immune function
and regulation (14). This region first received attention following
the discovery of cell surface molecules called the human leukocyte
antigens (HLA) involved in tissue graft and organ transplant rejec-
tion. HLA is now well-understood to have a primary functional
role in the protection against pathogens through selective binding
and presentation, in allele selective fashion, of processed peptides
to T lymphocytes critical to both cellular and humoral immune
responses.
Recent interrogation of the flanking regions led to the discov-
ery of additional MHC-relevant genes that extended beyond the
classically defined boundaries (15). This expansion resulted in a
region that is now referred to as the extended MHC (xMHC)
spanning 7.6 Mb and is divided into five subregions consisting
of the extended class I region at the telomeric end, and suc-
cessively the classical class I, III, and II clusters bounded by an
extended class II region at the centromeric end (Figure 1). While
the HLA superfamily of genes are among the most highly impli-
cated targets in disease susceptibility, they account for only a small
proportion of the estimated 252 expressed xMHC loci (15), includ-
ing genes involved in other immune response and inflammatory
processes (e.g., cytokines and complement factors), leukocyte mat-
uration, stress response, cell-cycle regulation, transcriptional and
translational machinery, and other cellular processes. Thus, strong
rationale exists supporting the need for comprehensive examina-
tions of the xMHC not limited only to the classical HLA loci,
FIGURE 1 | Schematic map (not to scale) of the 7.6 Mb extended
human MHC (xMHC) on the short (p) arm of human chromosome 6.
The HLA class I gene cluster includes the three expressed classical class I
genes, HLA-A, HLA-B, and HLA-C, and is located telomeric of the class III
region. The HLA class II gene cluster is located centromeric of the HLA
class III region. Of the over 250 known expressed loci of the xMHC, the
relative locations of only those that have appeared in previous studies of
childhood ALL are indicated.
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which historically have been given the most attention in disease
association studies.
Because childhood ALL is suspected to be caused by an adverse
immune response, possibly triggered by infectious exposures, and
because the xMHC includes a wide range of genes with potential
relevance to leukemogenesis, the xMHC is a highly appropriate
candidate region for investigation. Indeed, there is currently a
substantial collection of studies that have evaluated a potential
involvement of xMHC loci in childhood ALL risk. In this review,
we aimed to provide the reader with a synthesis of the current epi-
demiological evidence available to date regarding the association
between genetic variation of the xMHC and risk of childhood ALL.
CLASSICAL HLA GENES
Human leukocyte antigen is polygenic and encodes heterodimeric
cell surface glycoproteins involved in antigen presentation that
selectively interact, in a peptide-binding groove, with short peptide
fragments derived from non-self and self-proteins. The classical
HLA class I molecules (HLA-A, HLA-B, and HLA-C) present for-
eign antigens derived predominantly from intracellular infection,
and initiate CD8+ T-cell responses, while class II molecules (HLA-
DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-DQB1, HLA-
DQA1, HLA-DPB1, and HLA-DPA1) present antigens derived
from the extracellular space to CD4+ T helper cells, which, in turn,
activate macrophage and B-cells. The genes encoding HLA mole-
cules are highly polymorphic with up to many hundreds of alleles
segregating at a single locus (16). Because most are confined to the
region encoding the peptide-binding groove, the HLA polymor-
phisms have functional relevance and significance for disease sus-
ceptibility. Sequence homology and epitope sharing between alle-
les and loci in the HLA genes is evident from an inspection of the
sequences (17) for current alignments1. Selective pressures for bal-
anced polymorphism act to increase amino-acid diversity of HLA
molecules in populations, but stoichiometric constraints influence
the amino-acid make-up of an HLA molecule, and both influence
the types of peptides that can be bound by the HLA molecule (18).
Scrutiny of the HLA system in leukemia susceptibility in
humans began in the 1960s following landmark studies by Lilly and
colleagues who demonstrated that leukemogenesis by the Gross
leukemia virus in mice is strongly influenced by H-2 (the MHC
system in mice) type (19). Utilizing the best available typing meth-
ods and knowledge of the HLA system at the time, the earliest
studies in humans showed a link with class I loci such as HLA-
A2 antigen serotype (20–22), but were limited by relatively small
study populations and absence of restriction to age groups (i.e.,
children or adults) and sub-types. In addition, these studies used
low-resolution HLA typing methods based on serological recogni-
tion of cell surface antigens, which do not fully capture the allelic
diversity of HLA. Over time, with advances in understanding of
HLA genetics, development of higher resolution molecular typ-
ing techniques, and availability of well-defined study populations,
more refined and methodologically rigorous evaluations of HLA
in childhood leukemia susceptibility has been possible. Here, we
summarize the results of 23 previous studies, the first of which was
1http://www.ebi.ac.uk/ipd/imgt/hla
published in 1980, that specifically examined leukemia in children
in relation to genetic variation at the classical class I and class II
HLA loci (Table 1).
HLA CLASS I LOCI
HLA-A and HLA-B
With the exception of two reports (23, 24), studies of HLA-A,
HLA-B, and HLA-C associations with childhood ALL risk have
been based on serotypes rather than allelic level classifications.
The HLA-A2 antigen association found in the previous gener-
ation of studies of ALL (all age groups) was not observed in
subsequent studies conducted specifically in children. In one of
the earliest studies of HLA and childhood ALL risk, Davey et al.
(25) observed no difference in distribution of HLA-A and HLA-B
antigens between patients and controls. Among four additional
studies that investigated HLA-A antigens in childhood ALL (26–
29), only one reported an association with this locus, but with
the HLA-A23 serotype (29). An association with the HLA-B locus
was found in three of these studies (26, 28, 29), one of which was
a family-based study comprising 55 families with a child affected
with ALL (26). A comparison made between observed vs. expected
numbers of shared antigens among parents with ALL offspring
showed increased compatibility for HLA-B antigens, suggesting
a role for this locus as a recessive determinant. Using the case-
control design, one study reported higher HLA-B40 and lower
HLA-B5 antigen frequencies in Trinidadian cases compared to
controls (28), and another study conducted in Turkey reported a
reduced risk associated with the HLA-B7 antigen (29).
The lack of consistent results for HLA class I loci from these
mostly small studies (all less than 100 patients) utilizing low-
resolution HLA typing complicates interpretation. Addressing
these shortcomings, in the largest study to date evaluating HLA
and childhood ALL risk, Klitz et al. (24) utilized HLA allelic data
from the National Marrow Donor Program (NMDP) in an analysis
of 2,438 medically refractory childhood ALL patients being con-
sidered for or undergoing hematopoietic stem cell transplantation
and 41,750 controls that were matched on age (2–15 years), sex,
and geographical location in the United States. This comprehen-
sive analysis of the HLA-A and HLA-B loci revealed a spectrum of
HLA associations conferring predisposition to or protection from
refractory disease (Figure 2). Four significantly (p-value <0.01)
protective HLA-A alleles (A*33, A*01, A*03, and A*26) and six
predisposing-alleles (A*24, A*31, A*23, A*30, A*68, and A*74)
were found, with 50% of alleles as a whole either predisposing or
protective in this high-risk ALL population (Figure 2A). HLA-B
allelic associations revealed six protective alleles (B*14,B*38,B*08,
B*07, B*57, and B*44) and eight predisposing (B*15, B*18, B*40,
B*51, B*53, B*39, B*48, and a binned category “rare” with <50
copies) (Figure 2B). As with HLA-A, they showed a continuum of
odds ratios ranging from 0.57 to 3.20, with more predisposing than
protective alleles, and 24.0% of alleles being neutral with respect to
disease. These analyses show a spectrum of HLA associations and
indicate that studies with larger sample sizes might clarify the pre-
disposing, neutral, or protective status of alleles whose confidence
intervals are close to, or include, an odds ratio of 1.0. Further, each
allele may be regarded as a marker effect for sequences in LD with
the antigen.
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Table 1 | Studies evaluating the association between HLA genetic variation and ALL risk specifically in children.
Reference Region Study population Locus Main resultsa Comments
von Fliedner
et al. (35)
Switzerland 31 ALL; 123 controls HLA-DR (antigen) DRw7 over-represented in childhood
ALL compared to controls
Adult ALL and AML results
also available in report
Evidence of increased DRw7
homozygosity in patients vs. controls
Davey et al.
(25)
USA 94 ALL; 376 controls HLA-A (antigen)
HLA-B (antigen)
HLA-A and HLA-B antigens: no
difference in distribution between
groups
HLA-A9 associated with first
remission duration and
survival
von Fliedner
et al. (26)b
Switzerland 55 Families with
child affected with
ALL
HLA-A (antigen) HLA sharing among parents of
leukemic children was increased for
HLA-B (p=0.023) and HLA-DR
antigens (p=0.003) compared to
expected
Mating of certain shared
alleles in HLA is associated
with risk in offspring
HLA-B (antigen)
HLA-C (antigen)
HLA-DR (antigen)
Muller et al.
(27)
Germany 142 ALL (75, aged
<11 years)
HLA-A (antigen)
HLA-B (antigen)
HLA-C (antigen)
HLA-DR (antigen)
HLA-Cw7: higher frequency in ALL
compared to both control groups
(corrected p=0.00064)
p-Value corrected for multiple
comparisons (73 tests)
280 Local controls
1,053 Caucasian
controls
Difference was strong in ALL age
≥11 years compared to controls; in
children (age <11), not significant after
correction
Cameron et al.
(28)
Trinidad,
West Indies
10 ALL; controls HLA-A (antigen)
HLA-B (antigen)
HLA-C (antigen)
HLA-B40: higher frequency in ALL
compared to controls (p<0.05)
HLA-B5: no carriers in cases, but
37.8% in controls (p<0.05)
Taylor et al.
(42)
United
Kingdom
63 BCP-ALL; 92
adult and 82 infant
controls
HLA-DPB1 (4-digit
allele)
DPB1*02:01: RR=2.9, p<0.05
Patients are three to four times more
likely to be heterozygous for
DPB1*02:01/ *03:01,/ *04:01,/ *04:02
Dearden et al.
(48)
United
Kingdom
62 BCP-ALL; 76
newborn controls
HLA-DQB1 (4-digit
allele)
DQB1*05: RR=2.54, p=0.038
DQB1*0501: RR=2.18, p=0.095
DQB1*0501 more common in males
DQB1*0601 more common in females
DQB1*0501 and DPB1*0201
ALL association appeared
independent
Amino-acid motifs evaluated
Taylor et al.
(49)
United
Kingdom
62 BCP-ALL; 78
newborn controls
4-Digit allele Male-specific associations: Association with specific
HLA-DQA1 and HLA-DQB1
amino-acid motifs evaluated
HLA-DQA1
HLA-DQB1
DQA1*0101/ *0104: OR=4.06
(1.42–10.17)
DQA1*0201: OR=0.40 (0.18–0.96)
DQA1*03: OR=2.62 (1.07–6.02)
DQA1*0101 and DQB1*0501
co-occurrence: OR=3.73 (1.19–10.3)
Ghodsi et al.
(32)
United
Kingdom
94 BCP-ALL; 136
infant controls
HLA-C (typed for
NK1 or NK2 ligand)
NK1 and NK2 frequencies showed no
statistically significant difference
between ALL and controls
Excess of NK2 homozygous
patients compared to
controls, particularly in
females
Dorak et al.
(37)
United
Kingdom
114 ALL; 325
newborn controls
2-Digit allelic type:
HLA-DRB1
HLA-DRB4 (DR53)
HLA-DRB3 (DR52)
HLA-DRB5 (DR51)
Male-specific associations
DRB1*0401 (DR4): OR=2.9 (1.6–5.4)
DRB4*01 (DR53): homozygosity,
OR=11.7 (4.9–28.0)
DRB3 (DR52): OR=0.4 (0.2–0.7)
HLA-DRB1*04 is part of
DR53 supertype, thus, not
independent
Recessive nature of HLA
influences on childhood ALL
(Continued)
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Table 1 | Continued
Reference Region Study population Locus Main resultsa Comments
Taylor et al.
(43–45)
United
Kingdom
529–687 BCP-ALL
depending on study;
864 newborn
controls, 409
childhood solid
tumors
HLA-DPB1 (4-digit
allele and supertype)
DPB1*0201: OR=1.83 (1.34–2.41)
Other DPB1 alleles encoding peptide
motifs present in DPB1*02:01
associated
DPB1*01:01 associated with
TEL-AML1+ and hyperdiploid ALL
DP2 supertype: OR=1.7 (1.3–2.1)
DP8 supertype: OR=3.2 (1.5–7.0)
DP1 supertype: OR=0.5 (0.4–0.7)
DPB1*0601: OR=3.6 (1.5–8.6) and
associated with non-BCP-ALL
sub-types
Results indicated in table are
for BCP-ALL
Other ALL sub-types (pro-B
ALL, T-ALL, unclassifiable)
also evaluated
Amino-acid motifs evaluated
Multiple comparisons
considered in all analyses
Dorak et al.
(38)
Turkey 114 ALL; 118 controls 2-Digit allelic type: Male-specific associations Adult ALL results also
available in reportHLA-DRB1 DRB1*04: OR=3.08 (1.14–6.53)
HLA-DRB4 (DR53) DRB1*13: OR=0.32 (0.14–0.74)
HLA-DRB3 (DR52) DRB4 (DR53): OR=2.85 (1.42–5.70)
HLA-DRB5 (DR51) DRB3 (DR52): homozygosity,
OR=0.37 (0.15–0.89)
Yari et al. (39) Iran 22 ALL; 466 controls HLA-DRB1 (2-digit
allele)
DRB1*13: lower frequency in ALL
compared to controls (p=0.044)
Adult ALL results also
available in report
Moderate case-control
difference in frequency for
HLA-DRB1*04, not significant
Wang et al.
(40)
China 162 ALL; 1,000 cord
blood controls
HLA-DRB1*15 DRB1*15 : RR=1.51, p=0.018
HLA-DRB5
Morrison et al.
(33)
United
Kingdom
Mexico
UK: 114 ALL; 388
newborn controls
Mexico: 100 ALL;
253 adult controls
HLA-DRA
(rs3135388,
DRB1*1501 proxy)
HLA-C (rs9264942,
Cw5 proxy)
Class III loci
SKIV2L (rs419788)
TNXB (rs3130342)
Non-MHC locus
Female-specific associations
HLA-DRA (rs3135388): OR=2.6
(1.5–4.5)
HLA-C (rs9264942): OR=0.4 (0.2–0.7)
SKIV2L (rs419788): OR=1.8 (1.1–2.9)
TNXB (rs3130342): OR=2.2 (1.2–4.3)
Male-specific association
IFNG (rs2069727): OR=0.6 (0.4–1.0)
Focused on loci associated
with multiple sclerosis and
systemic lupus
erythematosus
Associations for SKIV2L and
TNXB were attenuated after
adjusting for HLA-DRA
IFNG (rs2069727)
Ozdilli et al.
(29)
Turkey 100 ALL; 90 AML;
100 controls
HLA-A (antigen)
HLA-B (antigen)
HLA-DRB1 (allele,
2-digit)
HLA-A23: RR=0.21 (0.04–1.03)
HLA-B7: RR=0.35 (0.13–0.96)
HLA-DRB1*04: RR=2.11 (1.13–3.96)
Gender-specific ALL
associations suggested
AML associated with
HLA-A11, HLA-B38, -B49, and
-DRB1*15
Hosking et al.
(23)
United
Kingdom
824 BCP-ALL; 4,737
adult controls
4-Digit allelic types:
HLA-A
No statistically significant associations
after correction for multiple testing
Six alleles associated at an
uncorrected p<0.05: HLA-A*26,
HLA-A*29, HLA-C*02, HLA-C*08,
DQB1*02, DQB1*03
HLA alleles imputed using a
reference database of SNP
haplotypes carrying known
HLA alleles
HLA-B
HLA-C
HLA-DQA1
HLA-DQB1
HLA-DRB1
(Continued)
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Table 1 | Continued
Reference Region Study population Locus Main resultsa Comments
Klitz et al. (24) USA 2,438 medically
refractory ALL;
41,750 adult donor
controls
2-Digit allelic types: Continuum of risk associations
observed for HLA-A, HLA-B, and
HLA-DRB1 loci (see Figure 2)
HLA-A
HLA-B
HLA-DRB1
Orouji et al.
(50)
Iran 107 ALL; 110
controls
HLA-DQB1 (allele) DQ2 (*02:01): RR=0.75, p=0.049 DQ5 also found associated
with adult ALL in this studyDQ5 (*05:01–*05:04): RR=1.89,
p=0.001
DQ7 (*03:01, *03:04): RR=1.48,
p=0.003
Urayama et al.
(47)
USA 585 ALL; 848
controls
4-Digit allele types: DPB1*01:01: OR=1.43 (1.01–2.04) Interaction observed between
DP1 supertype and 2 proxy
for immune modulation
HLA-DPA1 DP1 supertype in hyperdiploid ALL:
OR=1.83 (1.20–2.78)HLA-DPB1
aHLA nomenclature continues to evolve as information about its extraordinary genetic variation becomes available.The nomenclature in this table mostly reflects that
which was current at the time and used in the manuscripts cited.
bWith the exception of this one family-based study, all others in the table utilized a case-control study design.
FIGURE 2 | Risk of medically refractory childhood ALL according to 2-digit HLA alleles at HLA-A (A), HLA-B (B), and HLA-DRB1(C) (24). The vertical scale
is in ln(Odds) with odds values listed alone the top highlighted in blue for favorable and orange for predisposing-allele.
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Next, the authors classified genotypic groups according to
allelic composition, with alleles being protective, predisposing, or
neutral. Single allele effects for protective-neutral heterozygotes
and homozygous protective genotypes both conferred signifi-
cantly greater protection. In contrast, homozygous were signifi-
cantly more predisposing than heterozygous predisposing geno-
types. Haplotypes were similarly grouped, with homozygous
predisposing-allele haplotypes more disposed to medically refrac-
tory childhood ALL than heterozygous predisposing-allele hap-
lotypes. Haplotypes bearing favorable alleles revealed a different
pattern, with significant protection only from HLA-B haplotypes
with protective alleles, while the mixed predisposing/protective
haplotypes were neutral, suggesting that these cancel each other
out. Overall, these results indicate novel qualities of HLA loci
in medically refractory childhood ALL. In these analyses, HLA-A
appeared to have the weakest effect on ALL predisposition and pro-
tection in these children.HLA-B alleles show substantial protective
and predisposing effects, with stronger effects seen in homozygous
states. This continuum in disease susceptibility suggests a system
in which many alleles take part in disease predisposition based on
differences in binding affinity to one or a few peptides of exoge-
nous origin, adding to the numerous studies pointing to a role for
an infectious origin in childhood ALL.
HLA-C
Childhood ALL associations with HLA-C have also been reported,
but like the other class I loci, the associated antigens have not
been consistent across studies. Muller et al. (27) in a German
study compared ALL patients (all ages) to two different control
groups and found statistically significant associations with HLA-
Cw7 even after correction for multiple comparisons. However,
the association was less evident when restricted to patients less
than aged 11 years. Associations with HLA-Cw3 and HLA-Cw4
have also been noted in studies of ALL conducted among chil-
dren and adults (30, 31). Since different HLA types of a specific
locus may encode proteins with overlapping functional specifici-
ties, a situation of having multiple ALL-associated HLA types is
a possibility. Ghodsi et al. (32) examined this by distinguishing
HLA-Cw types with respect to whether they encode either NK1
or NK2, ligands that interact with receptors on natural killer cells.
The results did not support a role for the HLA-C locus in child-
hood ALL susceptibility. Building on previous observations of an
increased risk of ALL in children of women with autoimmune
disorders, Morrison et al. (33) specifically examined multiple
sclerosis and systemic lupus erythematosus risk markers. A child-
hood ALL association with the single nucleotide polymorphism
(SNP) rs9264942, a marker for HLA-Cw5, was found specifically
among females similar to the protective effect observed in multiple
sclerosis.
HLA CLASS II LOCI
HLA-DRB
Suggestion of a putative role of the HLA class II DR antigen on ALL
risk was first reported in the late 1970s (34) and showed an associ-
ation with DR7. Additional evidence specifically in childhood ALL
was available shortly after based on studies by Von Fliedner et al.,
one of which confirmed the DR7 association (35) and the other
showing a higher than expected sharing of DR antigens among
parents of children with leukemia (26).
Subsequent inspections at the allelic and supertype level of
HLA-DRB1, together with the expressed DR beta chain paralogs
(HLA-DRB3, -DRB4, and -DRB5) have yielded some of the most
consistent evidence to date of an HLA link with childhood ALL
risk. Dorak et al. (36) reported a strong male-specific childhood
ALL association with homozygosity for the HLA DR53 supertypic
antigen (encoded by HLA-DRB4), consistent with effects seen in
other major forms of leukemia such as chronic lymphocytic and
myeloid leukemia and acute myeloid leukemia (36). A few years
later, using an expanded series of cases and controls, these find-
ings were confirmed in a comprehensive examination of all DR
beta chain genes (37). An effect specifically in males was found
for DRB1*04, a common DRB1 allelic group, and part of the
DRB4 haplotype expressing the DR53 antigen. Examination of
DRB3, DRB4, and DRB5 (encoding the DR52, DR53, and DR51
supertypes, respectively) showed considerably higher DRB4*01
(DR53) homozygosity rates in patients compared to controls that
was specific to males. In addition, a decreased DRB3 frequency
was observed in patients compared to controls, again in males
only. These findings were subsequently replicated in an inde-
pendent series of high-risk and relapse childhood ALL patients
and controls and additionally noted marked protective effects
for DRB1*12 and DRB1*13, alleles linked to the DRB3 (DR52)
haplotypic group (38).
Additional evidence for a DRB1 association comes from three
other studies. Two of these, an Iranian (39) and a Turkish (29)
study,both showed protective and predisposing effects ofDRB1*13
andDRB1*04, respectively. The third was the large NMDP study of
European Americans described earlier (24). Similar to their find-
ings for the class I HLA-A and HLA-B loci, Klitz et al. described
a spectrum of associations at DRB1 with odds ratios ranging
from 0.77 to 1.84, and observed an imbalance toward predispos-
ing effects including DRB1*04,DRB1*14,DRB1*10, and DRB1*08
(Figure 2C).
Finally, DRB1*15, a risk allele for multiple sclerosis, has also
been implicated in the susceptibility to childhood ALL. At least two
recent studies have reported an association, one in a Chinese pop-
ulation comprising 162 childhood ALL cases and 1,000 controls
(40), and another in a UK population using the SNP rs3135388 as
a proxy for DRB1*15:01 (33). The latter study examined the effects
by gender and observed the association only in females, which is
consistent with a female-specific effect of the allele also seen in
multiple sclerosis (41).
HLA-DP
The first study to identify an association of HLA-DPB1 types with
childhood ALL was a preliminary study by Taylor et al. (42), based
on comparison of typing data from childhood common ALL cases
and two sets of controls (42). The study found that the allele
DPB1*02:01was more than twice as common among children with
ALL as in either set of controls. These findings were confirmed
and extended in 2002 (43) in the United Kingdom Childhood
Cancer Study (UKCCS) demonstrating that DPB1*02:01 was sig-
nificantly more common among a large series of 875 childhood
ALL patients than in either of two control groups (corrected
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p-value<0.05). A negative association of DPB1*01:01 with child-
hood ALL was also noted. Further, additional analyses generated a
global p-value<10−6 for a difference between HLA-DPB1 pheno-
type frequencies between common ALL and controls and indicated
that alleles other than DPB1*02:01 also contribute to susceptibil-
ity. The authors examined the distribution of key peptide-binding
residues in the pocket domains of these alleles,which indicated that
there was increased sharing of these between HLA molecules pre-
dicted to contribute to disease risk, compared to those encoded by
other alleles. Examination of the phenotype frequencies of specific
peptide-binding pocket residues demonstrated that significant
associations with childhood ALL susceptibility were almost exclu-
sively restricted to those peptide motifs present in DPB1*02:01;
with significantly different associations for total leukemias, total
ALL, common ALL, TEL-AML1+ ALL, and high-hyperdiploid
ALL, compared to controls.
In an extension of this work, Taylor et al. (44) defined six HLA-
DPB1 supertypes, based on amino-acid dimorphisms at positions
11 (G/L), 69 (E/K), and 84 (G/D) (Table 2), consisting of unique
peptide haplotypes encoded by the hypervariable second exon of
HLA-DPB1, which group alleles predicted to demonstrate func-
tional similarities with regard to antigen binding. Among the
UK childhood leukemia cases and controls, of the six super-
types examined, three (DP2, DP6, and DP8) showed evidence
of increased frequencies in cases, although this was only sig-
nificant in DP2 and DP8 after correction for multiple testing.
These two supertypes were also significantly increased in BCP-
ALL after correction, whereas DP6 appeared to be more common
among non-BCP leukemia cases (p-value= 0.007). Moreover, the
DP1 supertype frequency was much lower among BCP-ALL cases
(6.4%) compared to controls (11.1%; p-value <10−5), a find-
ing which did not extend to non-BCP leukemia. Stratification
of cases by age at diagnosis revealed a significant association
of the DP2 supertype with cases occurring at the typical peak
age for diagnosis for BCP-ALL (3–6 years; p-value= 10−4), but
not among cases diagnosed before 3 years or after 6 years of
age. By contrast, the decreased frequency of the DP1 super-
type was apparent in all groups of age at diagnosis. In a sepa-
rate analysis of supertype distributions in ALL sub-types (44), a
paucity of another DP1 supertype (GKD) was found among cases
with TEL-AML1+ and high-hyperdiploid karyotypes relative to
controls.
Further investigation of the association of the DP6 supertype
with leukemia (45) found that, of the seven alleles included in
this supertype, only DPB1*06:01 was significantly associated with
childhood leukemia (corrected p-value= 0.02), including total
ALL, AML, BCP-ALL, Pro-B ALL, and T-ALL. Further analyses
indicated that, of all DPB1 alleles and supertypes, DPB1*06:01
was the most strongly associated with leukemia. The genotype
DPB1*04:01/*06:01 is particularly strongly associated with ALL
(OR, 95% CI; 10.6, 2.4–47.4). Transmission disequilibrium tests
indicated that this allele was over-transmitted to children who
go on to develop leukemia (76.9%; p-value= 0.03). Subsequent
extended analysis of DPB1 allele transmission revealed no evi-
dence of over- or under-transmission of DP1 or DP2 supertypes
among UK leukemia cases, although there was a suggestion of
under-transmission of other rare alleles (46).
Table 2 | HLA class II DPB1 supertype distributions (percentage of
individuals carrying) reported in the UKCCS and NCCLS studies.
DPB1 supertypea NCCLS% UKCCS%
Cases Controls Cases Controlsb
DP2 (GEG) 24.8 24.5 18.3 13.3
DP4 (GKG) 79.2 80.9 82.9 72.4
DP6 (LED) 14.2 15.0 11.6 12.9
DP3 (LKD) 19.5 20.2 20.9 20.9
DP8 (GED) 3.4 2.2 2.4 0.8
DP1 (GKD) 16.2 12.7 13.5 17.7
UKCCS, United Kingdom Childhood Cancer Study; NCCLS, Northern California
Childhood Leukemia Study.
aSupertypes based on amino-acid dimorphisms at positions 11 (G/L), 69 (E/K), and
84 (G/D) (44).
bInfant controls.
More recently, Urayama et al. (47) investigated HLA-DP in
relation to childhood leukemia in the Northern California Child-
hood Leukemia Study (NCCLS), which includes an ethnically
heterogeneous sample consisting of two main populations; non-
Hispanic white and Hispanic. This study found no gross dif-
ferences in HLA-DPA1 allele frequencies or DPA1-DPB1 haplo-
types between cases and controls. However, analyses conditioned
on age, sex, and ethnicity identified a statistically significant
association with DPB1*01:01. Using the supertype classification
of Taylor et al. (44), this translated as an association of DP1,
with increased ORs in both non-Hispanic whites and Hispan-
ics, significant for high-hyperdiploid ALL (p-value= 0.005). In
contrast, Taylor et al. found the DP1 supertype was associated
with decreased risk. Importantly, as an extension beyond pre-
vious studies of HLA-DPB1 and childhood leukemia, the Cal-
ifornia study also examined interactions between proxies for
delayed infections in childhood (daycare attendance, ear infec-
tions, and breastfeeding) with the observed DP1 association.
Interactions were detected between DP1 and two proxies for
early immune modulation, older sibling (p-value= 0.036), and
breastfeeding (p-value= 0.094) in the risk of childhood ALL.
Although the power to detect interactions between DP1 and day-
care/ear infections in the first year was limited, the point esti-
mates were in the expected direction should the association be
related to delayed infection in childhood ALL, as hypothesized by
Greaves (4).
The observation of opposing effects of the DP1 supertype on
childhood ALL susceptibility in two apparently ethnically simi-
lar populations is intriguing, especially as both studies narrowed
the significant associations to the high-hyperdiploid subtype of
ALL. Comparison of supertype frequencies suggests heterogene-
ity between the two populations (Table 2). The DP1 supertype
appears to be less common in the NCCLS non-Hispanic white
controls (12.7%) compared with those employed in the UKCCS
(17.7%). Conversely, the frequency of DP2 is lower among UKCCS
controls (13.3%) compared to the NCCLS (24.5%) (Table 2).
These underlying differences may indicate differences in selective
pressure acting on the two geographically distinct populations,
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or alternatively be a consequence of other processes, such as
genetic drift.
HLA-DQ
In comparison to the other class II loci, there are relatively few
studies examining HLA-DQ in relation to childhood ALL risk.
Two of the three previous studies were based on the same study
population with an initial report by Dearden et al. (48) describing
for the first time an ALL association with the DQB1*05:01 allele
that was independent of their previously identified DPB1*02:01
effect. In their subsequent report, Taylor et al. (49) conducted a
more detailed examination of HLA-DQ that included the tightly
linked HLA-DQA1 locus. Their findings showed an increased risk
associated with DQA1*0101/*0104 exclusively in males and a pro-
tective effect associated with HLA-DQA1*0201. A joint analysis of
DQA1 and DQB1 indicated a strong effect associated with carriers
of both DQA1*0101/*0104 and DQB1*0501 and was seen only
in males. Interestingly, in a third DQB1 study conducted in Iran-
ian childhood ALL patients and controls by Orouji et al. (50), a
consistent predisposing effect was seen for DQB1*05 (DQ5), and
additionally a protective and predisposing effect for DQB1*02:01
(DQ2) and DQ7 (DQB1*03:01, *03:04), respectively.
CANDIDATE GENE STUDIES OF NON-HLA LOCI IN xMHC
The vast majority of genes in the xMHC that have been studied
with respect to childhood leukemia are HLA; however, a number
of non-HLA genes in the xMHC region have also been examined.
While in general these genes have not been studied in multiple
populations, they highlight the potential importance of genetic
variation in the xMHC in the etiology of childhood leukemia.
Han et al. (51) conducted a case-control study of the role of
immune response genes in total childhood leukemia in Korea.
Among the studied loci were two genes in or near the xMHC
region, TNF and NFKBIE (6p21.1). Using gene-wise analytical
methods to adjust for examination of multiple SNPs in each
gene, the authors observed no significant associations for any of
the genes included. This study included a relatively small sample
size (63 cases and 148 controls) and examined total childhood
leukemia, including ALL (59%) and AML (26%). Results for
individual leukemia sub-types were not presented.
Similarly, in a study of xenobiotic transport and metabolism
genes, Chokkalingam et al. (52) examined whether GPX6/GPXP3
(6p22.1) andTPMT (6p22.3) were associated with childhood ALL
risk among 377 cases and 448 controls. The authors found no sig-
nificant associations for the studied SNPs in these genes either
individually or in haplotype analyses.
In a study of genes involved in p53 signaling, Do et al. (53)
examined a number of loci within the xMHC region. Among
114 ALL cases and 414 controls, they found significant associa-
tions with SNPs in BAT3/BAG6, a molecular chaperone involved
in transcriptional control of the p53 tumor suppressor. However,
no associations were observed for other genes within the xMHC,
including DAXX, LTA, DDR1, and IER3.
The human hemochromatosis gene (HFE) modulates serum
iron levels, which have been linked to risk of several cancers.
Interestingly, evidence linking risk of childhood ALL to high birth-
weight has been reasonably consistent (54), and it is possible that
this observation may reflect or be modulated by serum iron levels.
In a study of 163 ALL cases and 995 controls, Dorak et al. (55)
explored this hypothesis and found that just one of 15 SNPs in
HFE was significantly associated with childhood ALL risk. This
SNP, rs9366637, in intron 1 of HFE, was also associated with
birthweight. However, among the 14 other studied SNPs were two
well-known functional SNPs, rs1800562, and rs1799945, which
were not associated with risk of childhood ALL.
Heat shock proteins are molecular chaperones that may play
a role in both adaptive and innate immune responses to tumors
and virus-infected cells. Ucisik-Akkaya et al. (56) examined func-
tional polymorphisms in three HSP genes that reside in the class III
region:HSPA1L,HSPA1A, andHSPA1B. Among 114 ALL cases and
414 controls from the UK, they found that rs1061581, in HSPA1B,
was significantly associated with childhood ALL risk. The associa-
tion was replicated in a separate set of 100 ALL cases and 253 con-
trols from Mexico (56). The authors noted that although this SNP
is in LD with HLA-DRB3, which was associated with childhood
ALL in the UK dataset, the HSPA1B association was independent
of HLA-DRB3. SNPs in HSPA1L and HSPA1A showed no signif-
icant associations with childhood ALL risk. Using the same UK
and Mexican populations, Morrison et al. (33) examined the role
of multiple sclerosis susceptibility factors in childhood ALL risk.
Included were two non-HLA genes in the xMHC region: SKIV2L
and TNXB, which were not found to have significant single SNP
associations with childhood ALL risk.
In summary, reports of childhood ALL risk associated with
non-HLA loci within the xMHC provide limited evidence that
the MHC may have relevance to childhood leukemia etiol-
ogy above and beyond the HLA. The reports described above
include a somewhat arbitrary and incomplete representation of
the non-HLA genes in the xMHC. Furthermore, with the excep-
tion of the Morrison et al. and Ucisik-Akkaya et al. reports,
which included independent replication populations, none of the
genes described in this section were examined in more than one
study population, and none were described in more than one
report.
xMHC ASSOCIATION MAPPING STUDIES
Hosking et al. (23) used data generated in the UKCCS genome-
wide association study (GWAS) to conduct an analysis of BCP-ALL
association across a 4.5-Mb xMHC region. They performed single
SNP comparisons, alongside a sliding window haplotype analysis
and imputation of HLA genotypes at the major class I (HLA-A, -B,
and -C) and class II (HLA-DQA1, -DQB1, and -DRB1) loci, with
data derived from UK population samples as controls (824 cases
and 4,737 controls). No associations, significant after correction
for multiple testing were observed; however, the strongest single
SNP-based association was with rs3135034 (p-value= 0.0017; not
significant after adjustment for multiple testing), which is approx-
imately 92 kb telomeric of HLA-DPB1, between the BRD2 and
HLA-DOA loci. In addition, after correction for multiple testing,
no significant associations were observed with imputed HLA alle-
les. The strongest (non-significant) associations were found for
A*26:01,A*29:02,B*14:02,C*02:02, andC*08:02 class I alleles and
DQB1*02:01, DQB1*03:02, DQB1*03:03, and DRB1*13:02 class II
alleles.
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Recently a high-density SNP analysis of the MHC region in
the NCCLS was conducted (57). In single SNP analyses this study
identified one locus, rs9296068, as significantly associated with
BCP-ALL risk after correction for multiple testing (OR= 1.40,
95% CI= 1.19–1.66, corrected p-value= 0.036). Of interest in the
context of the UKCCS MHC study (23), this SNP lies only approx-
imately 37 kb from rs3135034, the most strongly associated UK
xMHC SNP, upstream of the HLA-DOA transcription start site.
Sliding window haplotype analysis was also undertaken as part
of this study, yielding two significantly associated MHC haplo-
types, the first close to the TRIM27 gene in the extended class
I region (rs1237485-rs3118361-rs2032502-rs7747023; nominal
global p-value= 2.7× 10−5) and the second including rs9296068
and flanking HLA-DOA (rs423639-rs7754316-rs9296068; nomi-
nal global p-value= 9.2× 10−5). The haplotype showed little evi-
dence of correlation with the DP1 supertype, previously found to
be associated with ALL susceptibility in the same group of patients,
and analysis adjusting for carriers of the DP1 supertype indicated
an independent effect for rs9296068 (p-value= 3.0× 10−4). In
contrast to the Hosking et al. study, this investigation did not
extend to the imputation of additional SNPs in the MHC region
or the prediction of classical HLA types. This fact may have
contributed to the identification of significant associations not
apparent in the UK data; these may have been missed in the UK
study as a result of the additional burden of correction for multiple
testing.
Although the two SNPs identified in the UK and California
BCP-ALL MHC association studies were physically close to one
another, neither SNP showed any indication of association in the
reciprocal studies. However, the two SNPs flank a strong meiotic
recombination hotspot, known as DNA3 (58). It is established
that commonly used methods of genetic association mapping
would not be expected to identify associations under recombi-
nation hotspots, since they rely on positive LD, which hotspots
lack by definition. Hence, it is possible that these two SNPs tag a
HLA-DOA association in both populations, partially masked by
the strong DNA3 hotspot.
This hypothesis led to another study, consisting of a detailed
investigation of haplotypes and recombination rates in this region
of the MHC in UK childhood ALL cases and controls (Thompson
et al., submitted). Using the program PHASE (59) to predict hap-
lotypes and recombination rates among UKCCS ALL patients and
UK population controls from data generated in the UKCCS GWAS
(60), this study found evidence for an association with recombina-
tion rates at DNA3 and childhood ALL. Moreover, a novel analysis
using LDsplit (61) showed that loci on both sides of the hotspot,
including rs9296068 and rs3135034, contribute to recombination
at DNA3. Using data from an Icelandic study (62) the authors
demonstrated that recombination at DNA3 is strongly affected
by PRDM9 genotype, the relevance of which is underlined by a
recent publication demonstrating a marked increase in the preva-
lence of rare PRDM9 alleles among parents of childhood B-cell
ALL patients, and altered recombination patterns in patients, in
two North American populations (63).
Evidence from these analyses indicates that there are two phys-
ically close, but weakly linked risk loci for childhood ALL at
HLA-DOA and HLA-DPB1 in the MHC class II region, both
substantiated by results from two separate studies in the UK and
California. However, data from these studies are inconsistent in
terms of the nature of the HLA-DPB1 allelic associations with risk
of ALL and in the precise location of the association in the vicinity
of HLA-DOA. The former is complicated by apparent underly-
ing population differences in frequencies of HLA-DP, but may
be attributable to geographic variations in exposures to antigens
such as infectious agents. The weak but significant associations
in both studies with loci flanking the DNA3 meiotic recombi-
nation hotspot are suggestive of an association with HLA-DOA,
a molecule critical for HLA class II antigen processing, masked
by the breakdown of LD in this region. The increased rates of
recombination at DNA3 may further exacerbate the heterogene-
ity of genotypes at this locus. Previously identified functionally
important variants within recombination hotspots have been asso-
ciated with recombination mediated sequence alterations (64, 65);
it remains to be determined whether this applies to HLA-DOA in
the context of childhood ALL.
CONCLUSION AND FUTURE DIRECTIONS
Results based on mostly low-resolution genotypes and HLA tech-
nology that has evolved over time, compounded by small study
sizes and conducted independently across populations of differ-
ent ancestral backgrounds, present challenges to fully interpreting
the collective HLA evidence. Thus far, there appear to be no strik-
ing childhood ALL genetic susceptibility loci in the xMHC that are
similar in nature and magnitude to those seen for autoimmune and
infectious diseases. However, mounting evidence does suggest that
more modestly associated susceptibility loci showing population
and subtype specificity may exist. In particular, this is exempli-
fied by multiple previous studies showing male-specific effects
for DR53 and evidence of HLA-DPB1 BCP-ALL associations with
potentially more detectable effects when in the presence of certain
environmental exposures. A role forHLA-DPB1 or a gene localized
to that region is also supported by two independent mapping stud-
ies of the xMHC demonstrating a need for targeted fine-mapping
efforts. Further, a highly powered study of children with med-
ically refractory ALL, those being considered for or going to stem
cell transplantation, has revealed highly significant associations to
both HLA class I (HLA-A and -B) and class II (HLA-DRB1), results
which may shed light on the role of HLA in the less severe disease
form of pediatric ALL. While this is a noteworthy study due to its
methodological rigor that is unique over previous studies, valida-
tion in comparable and appropriately large study populations is
still required.
There are several opportunities for improvement in future
studies given our currently expanded knowledge of the genetic
complexities of the xMHC (14, 66, 67), technological advances
in genomic characterization and high-resolution HLA genotyping
(68), and increased recognition of the importance of international
collaboration and independent validation (69). The genomic com-
plexities of the xMHC, such as long-range LD that gives rise to
extended haplotypes and extensive genetic variation of the region,
are now well-characterized and facilitate the initial localization
of genomic regions, but complicate the effort to fine-map causal
genetic loci to disease risk (70). The classical HLA genes are the
most widely studied of the xMHC loci and have been associated
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with dozens of diseases, but in many cases, including childhood
ALL, it is not clear whether the associations can be unambiguously
linked to the HLA gene or instead indicate an association with
an adjacent causal locus in LD. To address this, comprehensive
examination of genetic variability of the entire xMHC, includ-
ing high-resolution HLA allelic typing, is needed and is currently
achievable using recently developed technologies. High-density
MHC SNP genotyping studies, two of which were described in
this review (23, 57), are a step in this direction, but they lacked
direct allelic typing of all classical HLA loci. The UKCCS applied
previously derived methods (71, 72) to impute HLA alleles based
on GWAS-derived SNPs for six of the nine classical HLA loci.
While this is a reasonable alternative to a costly and intensive HLA
allelic typing effort of all loci, whether such imputation methods
can replace classical typing is still questionable and should be con-
sidered on an individual study basis depending on sample size,
ancestral composition of the study population, and availability of
SNP and HLA data from a suitable reference panel (73).
Methods for routine next-generation DNA sequencing-based
HLA typing have recently been developed (68) and provide the
highest quality and resolution of allelic types without the need
for time-consuming efforts to resolve allelic ambiguities in het-
erozygotes. Full implementation of these methods has recently
been applied to a case-control study of follicular lymphoma,
demonstrating their feasibility for use in disease association stud-
ies (74). With rapidly falling costs, next-generation sequencing of
the xMHC appears to be a feasible and efficient strategy for future
comprehensive examination of the region in childhood ALL.
It should be noted, however, this ability to test a large number
of markers simultaneously, including up to hundreds of high-
resolution allelic types for a single HLA locus presents a major
concern regarding increased probabilities of false-positive findings
due to the multiple tests being conducted. A few available meth-
ods for addressing multiple testing include Sidak and Bonferroni
corrections, controlling the false-discovery rate, and permutation-
based methods (75, 76), but these criteria for defining a sta-
tistical significance threshold, in return, put a greater strain on
statistical power and sample size requirements. Careful consid-
eration of these requirements, particularly for a rare disease like
childhood ALL that appears to benefit from gender-specific and
gene-environment interaction evaluation, and the importance of
independent replication, suggests the need for coordinated stud-
ies and collaboration to fully characterize the role of the xMHC
in childhood ALL risk. The Childhood Leukemia International
Consortium (CLIC2), which currently includes 22 epidemiologi-
cal studies of childhood leukemia representing 12 countries, was
formed in 2005 to facilitate collaborative efforts such as those
needed for genetic studies (69). Furthermore, because the exten-
sive LD patterns across the xMHC show population-specificity
(70, 77) that vary in the breakdown of conserved sequences, the
comparison of multiple homogenous populations of different
ancestries can aid in the fine-mapping effort of disease loci (78).
Although the xMHC was one of the first candidate regions
examined in childhood ALL over three decades ago, only during
2https://ccls.berkeley.edu/clic
these last several years have sufficient advances in understanding
of the xMHC been made to permit comprehensive and definitive
studies in evaluating its role in childhood ALL. Given the persis-
tent epidemiological support for an infection-related cause, the
inconsistent but suggestive evidence of the xMHC and childhood
ALL literature, and clear opportunities for application of the most
recent knowledge and technologies, we believe that future stud-
ies are warranted and have tremendous potential for elucidating
the role of this complex region in the genetic susceptibility of
childhood ALL.
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